-Transforming STI Screening with a Tiered Multiplex Diagnostic Portfolio in Alignment with 2025–2026 WHO Guidelines

1. The Iceberg Beneath the Surface

This week, April 12–18, 2026, marks STI Awareness Week. The theme of this week serves as a powerful reminder: the global burden of sexually transmitted infections (STIs) remains profoundly underestimated. According to World Health Organization (WHO) estimates, there are more than 1 million new curable STI cases every day among people aged 15–49 years, amounting to over 374 million new cases annually. However, the full spectrum of STI pathogens extends far beyond the four classic curable infections (chlamydia, gonorrhoea, syphilis, and trichomoniasis). It encompasses a diverse array of bacteria (e.g., Mycoplasma genitalium, Ureaplasma species, Gardnerella vaginalis, Group B Streptococcus), viruses (herpes simplex virus types 1 and 2), protozoa (Trichomonas vaginalis), and fungi (Candida species) — many of which are not captured in traditional syndromic or single-pathogen testing paradigms.

The stealthy nature of asymptomatic infection remains a core challenge in global STI control. These silent infections not only insidiously progress to pelvic inflammatory disease, ectopic pregnancy, infertility, and adverse pregnancy outcomes, but also serve as persistent transmission reservoirs, fuelling the emergence of antimicrobial resistance — most critically for N. gonorrhoeae, for which ceftriaxone is now the last effective option in many countries.

Against this backdrop, WHO released in July 2025 two landmark evidence-based guideline modules: the Guidelines for the Management of Asymptomatic Sexually Transmitted Infections[1] and the Recommendations on the Delivery of Health Services for STI Prevention and Care[2]. These were followed in February 2026 by the WHO Consolidated Operational Handbook on Sexually Transmitted Infections[3], which consolidates all existing normative guidance across the full STI prevention and care cascade. Additionally, the Overview of WHO recommendations on HIV and sexually transmitted infection testing, prevention, treatment, care and service delivery[4] provides a comprehensive synthesis of current guidance. Together, these documents signal a clear direction: expand nucleic acid amplification test (NAAT)-based STI screening coverage, particularly among asymptomatic populations, and adopt more efficient, accessible, and integrated testing strategies — including multiplex assays that cover a broad range of pathogens in a single test.

This article builds on the STI multiplex molecular diagnostic portfolio of Macro & Micro-Test Biotech Co., Ltd., aligned with the latest WHO evidence-based guidance. It systematically presents a tiered testing approach — from single-target detection, triplex, 9-plex, 14-plex, to 18-plex assays — and demonstrates how precise, flexible, and efficient strategies can address the screening needs of asymptomatic STIs across different clinical scenarios.

1. Core Evidence from the Latest WHO Guidelines and Implications for Diagnostic Technology

2.1 Evidence-Based Recommendations for Asymptomatic STI Screening

The Guidelines for the Management of Asymptomatic Sexually Transmitted Infections (July 2025)[1], developed using the GRADE methodology with systematic reviews and expert evaluations, focuses specifically on evidence-informed recommendations for screening N. gonorrhoeae and C. trachomatis. The guidelines explicitly recommend targeted screening in key populations where resources are available, including pregnant women, sexually active adolescents and young people aged 10–24, sex workers, and men who have sex with men (MSM). Screening frequency recommendations specify at least annual screening for sex workers and MSM, or every six months where feasible.

The release of these guidelines marks a paradigm shift in global STI strategy — from “symptom-driven” to “active screening.” As Dr Meg Doherty, Director of WHO’s Global HIV, Hepatitis and STIs Programmes, stated: “These new recommendations aim to close persistent policy and service gaps, especially for asymptomatic STIs, and help countries move faster toward the 2030 goals”[1].

2.2 Service Integration and the Global Consensus on Multiplex Testing

The concurrently released Recommendations on the Delivery of Health Services for STI Prevention and Care (July 2025)[2] promotes people-centred health services through four pillars: decentralization, integration, task sharing, and digital health. Notably, in September 2025, WHO announced the formation of a Guideline Development Group to develop the first-ever evidence-based global guidelines on multiplex testing, specifically addressing HIV, viral hepatitis, and STIs[5]. WHO defines multiplex testing as “a process that uses one sample and a single assay or platform to detect multiple infections at the same time” and notes that it is “a promising strategy to improve efficiency, expand testing coverage across diseases, and enhance cost-effectiveness”[5].

This signals that multiplex NAAT has evolved from a laboratory technique into a core tool for global public health strategy. In resource-limited settings, leveraging single-sample, single-run multi-pathogen screening will greatly enhance testing accessibility and cost-effectiveness — particularly suited to large-scale screening of asymptomatic populations and regular surveillance of high-risk groups.

2.3 The 2026 Consolidated Operational Handbook: A Strategic Mandate for Multiplex Testing

The WHO Consolidated Operational Handbook on STIs (February 2026)[3] provides an operational framework for integrating STI services across primary care, community, HIV, reproductive health, and maternal-child health platforms. For diagnostic strategy, three key mandates emerge:

Integration across platforms — requiring diagnostic tools that work reliably with multiple sample types (urine, urethral, cervical, vaginal swabs)

Sustainable financing — as countries shift from donor support to domestic budgets, cost-efficiency becomes critical. Multiplex NAAT reduces per-pathogen reagent cost, hands-on time, and turnaround time compared to multiple single-target assays, enabling expanded coverage without proportional infrastructure investment.

Antimicrobial stewardship — comprehensive pathogen identification supports targeted therapy over empirical treatment, a key strategy to slow N. gonorrhoeae antimicrobial resistance. 

3. Macro & Micro-Test Tiered STI Screening Product Portfolio

3.1 Design Philosophy: From Single-Target Precision to Panoramic Coverage

Based on the evidence-based requirements for asymptomatic STI screening from WHO guidelines[1,2,4] and the global consensus on multiplex testing as a public health strategy[5], Macro & Micro-Test has built a tiered STI nucleic acid testing portfolio from single-target to ultra-broad-spectrum detection. All products utilize Fluorescence PCR or Enzymatic Probe Isothermal Amplification (EPIA) platforms, with sample types covering urine, male urethral swabs, female cervical swabs, and vaginal swabs, accommodating diverse clinical scenarios and population screening needs.